Small Molecules for Precision Medicine

Learn More about Arqule

We are pursuing multiple programs in biomarker-defined oncology and rare disease indications

Targeted Approach to Cancer

Clinical Trials

Research & Development

Product Pipeline

Targeted Approach To

Rare Diseases

News & Events

Proteus Syndrome Treatment

ArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and Mutant BTK, at the 2016 Pan Pacific Lymphoma Conference

September 21, 2016

ArQule to Present at The Leerink Partners Rare Disease and Immuno-Oncology Roundtable on September 28, 2016

More News & Events »